MedPath

The Effects of Early Life PUFA and R-TFA on AD: A Systematic Review and Meta-analysis

Completed
Conditions
Allergic Disorder
Interventions
Other: PUFA and R-TFA
Registration Number
NCT03344783
Lead Sponsor
Sun Yat-sen University
Brief Summary

The purpose of this study is to evaluate whether early life natural exposure to fatty acid affects the AD risk.

Detailed Description

The prevalence of Allergic Diseases (AD) is rising dramatically worldwide especially in more industrialized countries during the past two decades, representing a substantial disease burden of individuals and health service cost. Early life nutritional exposures could modify the gene expression and susceptibility of allergic diseases (AD), yet the effects of early life polyunsaturated fatty acids (PUFA) and ruminant trans fatty acids (R-TFA) on AD remain unclear.Therefore,the investigators performed the meta-analysis and systematic review to evaluate whether early life natural exposure to PUFA and R-TFA affects the AD risk.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
26
Inclusion Criteria
  • Studies needed to provide endpoints of AD, and risk estimates [odds risk (OR), relative risk (RR) or hazard ratio (HR)] for PUFA or R-TFA as the exposure. We included English language articles only, while scanned titles /abstracts of non-English language articles to evaluate agreement with the results published in English.
Exclusion Criteria
  • Studies were excluded if they didn't report the profile of PUFA or R-TFA, or if they targeted participants with medical condition.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
mother-children pairsPUFA and R-TFA-
Primary Outcome Measures
NameTimeMethod
Allergic rhinitis were determined by using the validated International Study of Asthma and Allergic in Children (ISAAC) questionnaire or doctors' diagnosis.From date of inclusion of pregnant women cohort until the date of allergic rhinitis' diagnosis in children,follow-up time up to 18 years

Parental reported questions adapted from the International Study on Asthma and Allergy in Childhood (ISAAC) provided information on allergic rhinitis.Researchers combined questions into current allergic rhinitis (no, yes).

Eczema were determined by using the validated International Study of Asthma and Allergic in Children (ISAAC) questionnaire or doctors' diagnosis.From date of inclusion of pregnant women cohort until the date of eczema' diagnosis in children,follow-up time up to 18 years

Parental reported questions adapted from the International Study on Asthma and Allergy in Childhood (ISAAC) provided information on eczema.Researchers combined questions into current eczema (no, yes).

Wheeze were determined by using the validated International Study of Asthma and Allergic in Children (ISAAC) questionnaire or doctors' diagnosis.From date of inclusion of pregnant women cohort until the date of wheeze' diagnosis in children,follow-up time up to 18 years

Parental reported questions adapted from the International Study on Asthma and Allergy in Childhood (ISAAC) provided information on wheeze.Researchers combined questions into current wheeze (no, yes).

Asthma were determined by using the validated International Study of Asthma and Allergic in Children (ISAAC) questionnaire or doctors' diagnosis.From date of inclusion of pregnant women cohort until the date of asthma' diagnosis in children,follow-up time up to 18 years

Parental reported questions adapted from the International Study on Asthma and Allergy in Childhood (ISAAC) provided information on asthma.Researchers combined questions into current asthma (no, yes).

Sensitization were determined by IgE test.From date of inclusion of pregnant women cohort until the date of sensitization' diagnosis in children,follow-up time up to 18 years

A child was considered sensitized if the IgE level for at least one of the seven allergens was ≥0.35 kUA/l, and nonsensitized if IgE level for all seven allergens was \<0.35 kUA/l.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Weijia, Wu

🇨🇳

Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath